AFMD News and Press, Affimed N.V. From 07/31/23

Stable disease was observed in three out of seven heavily pretreated patients No dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), ...

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and has been accepted for poster presentation An encore oral presentation will share the safety an...

2023-06-04 08:00:00 ET Summary Affimed's cash and cash equivalents stand at $166.7 million, sufficient to support operations until 2025, but the company faces potential delisting from Nasdaq due to non-compliance with the minimum bid price rule. The company's clinical trials, incl...

Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohort AFM24 showed clinical activity in 7 out of 15 heavily pre-treated patients with tumor reductions, including 2 confirmed partial responses and 5 patients e...

HEIDELBERG, Germany, May 30, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Of...

AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients with EGFR mutant NSCLC; updated interim analysis data of 15 patients from the NSCLC cohort will be presente...

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

2023-05-24 12:39:00 ET Are you new to penny stocks? Do you want to know how to use momentum and stock market volatility to your advantage? In many instances, there are hidden opportunities with low-priced stocks, and savvy traders seek to uncover the next big winners. In this article, we wi...

2023-05-23 12:36:04 ET Affimed N.V. (AFMD) Q1 2023 Earnings Conference Call May 23, 2023, 08:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smit...

2023-05-23 07:16:13 ET German biotech Affimed N.V. ( NASDAQ: AFMD ) announced Tuesday that the FDA cleared an Investigational New Drug Application (IND) permitting a Phase 2 trial to study its innate cell engager AFM13 as a combination therapy for certain patients with Hodgkin Lymph...